Trial reportJournal of acquired immune deficiency syndromes (1999)2012
A randomized controlled trial assessing the effects of raltegravir intensification on endothelial function in treated HIV infection.
Trial report in Journal of acquired immune deficiency syndromes (1999), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00843713 (A Randomized, Controlled Trial Assessing the Effects of Raltegravir Intensification on Endothelial Function in Treated HIV Infection), which is not on this map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized, Controlled Trial Assessing the Effects of Raltegravir Intensification on Endothelial Function in Treated HIV Infection
Who cites it
25 citing papers in PubMed, 38 citations in OpenAlex.
- HIV-1 DNA decay dynamics in blood during more than a decade of suppressive antiretroviral therapy.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2014Trial
- Increase in 2-long terminal repeat circles and decrease in D-dimer after raltegravir intensification in patients with treated HIV infection: a randomized, placebo-controlled trial.The Journal of infectious diseases · 2013Trial
- Effects of switching from efavirenz to raltegravir on endothelial function, bone mineral metabolism, inflammation, and renal function: a randomized, controlled trial.Journal of acquired immune deficiency syndromes (1999) · 2013Trial
- Review
- Review
- Inverted CD8 T-Cell Exhaustion and Co-Stimulation Marker Balance Differentiate Aviremic HIV-2-Infected From Seronegative Individuals.Frontiers in immunology · 2021Article
- HIV infection and coronary heart disease: mechanisms and management.Nature reviews. Cardiology · 2019Review
- T-cell exhaustion in HIV infection.Immunological reviews · 2019Review
- Immune checkpoint blockade in infectious diseases.Nature reviews. Immunology · 2018Review
- The latest evidence for possible HIV-1 curative strategies.Drugs in context · 2018Review
- Coronary Artery Disease in HIV-Infected Patients: Downside of Living Longer.Current atherosclerosis reports · 2017Review
- Impact of Different Antiretroviral Strategies on Total HIV-DNA Level in Virologically Suppressed HIV-1 Infected Patients.Current HIV research · 2017Article
- HIV infection, antiretroviral therapy, and measures of endothelial function, inflammation, metabolism, and oxidative stress.PloS one · 2017Article
- The role of HIV integration in viral persistence: no more whistling past the proviral graveyard.The Journal of clinical investigation · 2016Review
- Telmisartan to reduce cardiovascular risk in older HIV-infected adults: a pilot study.HIV clinical trials · 2015Article
- Influence of immune activation and inflammatory response on cardiovascular risk associated with the human immunodeficiency virus.Vascular health and risk management · 2015Review
- Gut epithelial barrier dysfunction and innate immune activation predict mortality in treated HIV infection.The Journal of infectious diseases · 2014Article
- Reply to Karch et al.The Journal of infectious diseases · 2014Article
- Arterial disease in patients with human immunodeficiency virus infection: what has imaging taught us?JACC. Cardiovascular imaging · 2014Review
- Can early therapy reduce inflammation?Current opinion in HIV and AIDS · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 2 countries.
Funding
Abstract
objectivesTo determine whether intensification with raltegravir improves endothelial function in antiretroviral-treated HIV-infected individuals.
design: Randomized, double-blinded, placebo-controlled study.
methodsFifty-six subjects with treatment-mediated viral suppression for at least 1 year were randomized to add 400 mg of raltegravir twice daily or matching placebo for 24 weeks. The primary endpoint was the difference in rate of change in endothelial function [as assessed by flow-mediated vasodilation (FMD) of the brachial artery] from baseline to week 24 between the raltegravir and placebo groups. Linear mixed models were used to evaluate the association of treatment group with changes in FMD, immune activation, and measures of viral persistence.
resultsAt baseline, the median CD4 T-cell count was 498 cells/mm, nadir CD4 T-cell count was 191 cells/mm, duration of HIV infection was 18 years, FMD was 3.3%, and hyperemic velocity (a marker of microvascular function) was 68.3 cm. There were no significant differences between treatment groups in rate of change in FMD (raltegravir group: +0.032% per week, placebo group: +0.023% per week; P = 0.60). There were also no differences between treatment groups in rate of change in hyperemic velocity, immune activation, or viral persistence. In multivariable analysis, older age, longer duration of HIV infection, and current abacavir use were associated with lower FMD. Lower CD4 T-cell count and current abacavir use were associated with lower hyperemic velocity.
conclusionsThe addition of raltegravir to suppressive antiretroviral therapy did not have a significant impact on cardiovascular risk, as assessed by endothelial function (ClinicalTrials.gov NCT00843713).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.